WalshJHeinemannL. Optimizing duration of usage of insulin infusion sets: impact of mechanical stress on infusion sites and identifying individuals with IIS issues. J Diabetes Sci Technol. 2025;19(1):3-4. doi:10.1177/19322968241233607.
2.
ZhangGCohenOChattarajS. Development of the extended infusion set and its mechanism of action. J Diabetes Sci Technol. 2024;18(2):454-459. doi:10.1177/19322968221112120.
3.
EvertABBodeBWBuckinghamBA, et al. Improving patient experience with insulin infusion sets: practical guidelines and future directions. Diabetes Educ. 2016;42(4):470-484. doi:10.1177/0145721716642526.
4.
KwaTZhangGShepardKWherryKChattarajS. The improved survival rate and cost-effectiveness of a 7-day continuous subcutaneous insulin infusion set. J Med Econ. 2021;24(1):837-845. doi:10.1080/13696998.2021.1945784.
5.
KwaTZhangGKiehlJ, et al. 8654 real-world performance of the medtronic extended infusion set in the United States. J Endocr Soc. 2024;8(suppl 1):1. doi:10.1210/jendso/bvae163.906.
6.
HeltonKLRatnerBDWisniewskiNA. Biomechanics of the sensor-tissue interface-effects of motion, pressure, and design on sensor performance and the foreign body response-part I: theoretical framework. J Diabetes Sci Technol. 2011;5(3):632-646. doi:10.1177/193229681100500317.
